News
Cantor Fitzgerald Reiterates Overweight on Harmony Biosciences, Maintains $49 Price Target
12 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Needham Reiterates Buy on Harmony Biosciences, Maintains $50 Price Target
11 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Harmony Biosciences Announces Exclusive Agreement To Develop And Commercialize TPM-1116, A Highly Potent And Selective Oral Orexin-2 Receptor Agonist; Harmony Will Pay Bioprojet An Upfront License Fee Of $25.5M For The Exclusive Right
11 Apr 24
Biotech, News, Contracts, General
Needham Reiterates Buy on Harmony Biosciences, Maintains $50 Price Target
9 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Harmony Biosciences, Maintains $49 Price Target
28 Mar 24
News, Price Target, Reiteration, Analyst Ratings
Mizuho Maintains Buy on Harmony Biosciences, Lowers Price Target to $40
27 Feb 24
News, Price Target, Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Harmony Biosciences, Maintains $49 Price Target
23 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Needham Maintains Buy on Harmony Biosciences, Lowers Price Target to $50
23 Feb 24
News, Price Target, Analyst Ratings
Analyst Ratings For Harmony Biosciences
22 Feb 24
Analyst Ratings
Needham Reiterates Buy on Harmony Biosciences, Maintains $53 Price Target
22 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Harmony Biosciences Q4 2023 Adj EPS $0.73 Beats $0.48 Estimate, Sales $168.41M Miss $169.06M Estimate
22 Feb 24
Earnings, Earnings Beats, Earnings Misses, News
Earnings Scheduled For February 22, 2024
22 Feb 24
Earnings
Mizuho Maintains Buy on Harmony Biosciences, Raises Price Target to $42
16 Feb 24
News, Price Target, Analyst Ratings
Press releases
HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024
16 Apr 24
Press Releases
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST
11 Apr 24
Press Releases
HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME
3 Apr 24
Press Releases
HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE
26 Mar 24
Press Releases
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
28 Feb 24
Press Releases
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
22 Feb 24
Earnings, Press Releases
U.S. FOOD AND DRUG ADMINISTRATION GRANTS PRIORITY REVIEW TO HARMONY BIOSCIENCES' APPLICATION FOR WAKIX® (PITOLISANT) IN PEDIATRIC NARCOLEPSY
21 Feb 24
Press Releases
HARMONY BIOSCIENCES TO REPORT FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS ON FEBRUARY 22, 2024
8 Feb 24
Press Releases